当前位置: X-MOL 学术Cell. Mol. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical development of CAR T cell therapy in China: 2020 update
Cellular & Molecular Immunology ( IF 21.8 ) Pub Date : 2020-09-30 , DOI: 10.1038/s41423-020-00555-x
Jianshu Wei 1 , Yelei Guo 1 , Yao Wang 1 , Zhiqiang Wu 1 , Jian Bo 2 , Bin Zhang 3 , Jun Zhu 4 , Weidong Han 1
Affiliation  

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative reference for colleagues in the field, and a better understanding of the history and current situation will help us more reasonably conduct research and promote cooperation.

更新日期:2020-09-30
down
wechat
bug